Drug Discovery

GSK collaborates with Sanofi to develop COVID-19 vaccine

British drugmaker GlaxoSmithKline (GSK) has joined forces with French pharma company Sanofi for the development of an adjuvanted vaccine for COVID-19 disease.

Alnylam to secure $2bn from Blackstone to advance RNAi medicines

Alnylam Pharmaceuticals has entered into a $2bn strategic financing collaboration with Blackstone to advance the commercial potential of RNA interference (RNAi) therapeutics.

Enzychem Lifesciences announces filing of US provisional patent for EC-18 to treat COVID-19

Enzychem Lifesciences announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering treating COVID-19 infections and symptoms using EC-18, the Company's lead compound.

Alnylam and Dicerna form RNAi Therapeutics collaboration on alpha-1 liver disease

Alnylam Pharmaceuticals and Dicerna Pharmaceuticals have formed a development and commercialization collaboration on investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin (A1AT) deficiency-associated liver disease (alpha-1 liver disease).

Gilead Sciences, Second Genome announce strategic collaboration in biomarker and inflammatory bowel disease drug discovery

Gilead Sciences and Second Genome, a leader in microbiome science, announced that the companies have entered into a four-year strategic collaboration to identify biomarkers associated with clinical response in up to five of Gilead’s pipeline compounds in inflammation, fibrosis and other diseases, and to identify potential new targets and drug candidates for the treatment of inflammatory bowel disease (IBD).

GSK collaborates with Vir Biotechnology for COVID-19 treatments

GlaxoSmithKline (GSK) has collaborated with Vir Biotechnology for the research and development of solutions for coronaviruses.

Shenogen enters into an exclusive license with BioArdis to develop and commercialise FGFR4 kinase inhibitor for Asian market

Shenogen has entered into an exclusive collaboration and licensing agreement with Shanghai BioArdis and BioArdis for the development and commercialization of BioArdis' novel FGFR4 (fibroblast growth factor receptor 4) kinase inhibitor, BIO-1262/SNG-203, either as monotherapy or combination therapy in Mainland China, Hong Kong, Macau and Taiwan.

Vir and Alnylam expand collaboration to advance investigational RNAi therapeutics targeting host factors for treatment of COVID-19

Vir Biotechnology and Alnylam Pharmaceuticals, Inc. announced an expansion to their broad multi-target existing collaboration for the development and commercialization of RNAi therapeutics for infectious diseases, including SARS-CoV-2, the virus that causes the disease COVID-19.

Novartis unveils plans to begin trial with Jakavi in severe COVID-19 patients

Novartis has unveiled plans to commence a clinical trial of Jakavi (ruxolitinib) in severe COVID-19 patients and establish an international compassionate use programme.